News >

Rituximab Biosimilar Shows Equivalency in CD20+ Non-Hodgkin Lymphoma

Gina Columbus @ginacolumbusonc
Published: Thursday, Aug 22, 2019

David M. Reese, MD

David M. Reese, MD
ABP 798, a rituximab (Rituxan) biosimilar, demonstrated clinical equivalency to reference rituximab in patients with CD20-positive B-cell non-Hodgkin lymphoma, according to topline results from the comparative phase III JASMINE study (NCT02747043).1

 

References

  1. Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab). Amgen. Published August 22, 2019. https://bit.ly/2L0pACF. Accessed August 22, 2019.
  2. McBride H, Maher G, Sweet H, Foltz I, Kuhns S. Functional similarity of proposed biosimilar ABP 798 with rituximab. Blood. 2017;130:5001. bloodjournal.org/content/130/Suppl_1/5001.
  3. Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab. Amgen. Published January 24, 2019. https://bit.ly/2FVzjct. Accessed January 24, 2019.
  4. FDA Approves Pfizer’s Biosimilar, RUXIENCE (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions. Pfizer. Published July 23, 2019. https://bwnews.pr/2Sxzvmo. Accessed July 23, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x